Literature DB >> 29215617

Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma.

Andreas Varkaris1,2,3, David W Lewis4, Francis W Nugent5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29215617     DOI： 10.1038/ajg.2017.387

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

1.  Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.

Authors:  Julien Calderaro; Benoît Rousseau; Giuliana Amaddeo; Marion Mercey; Cécile Charpy; Charlotte Costentin; Alain Luciani; Elie-Serge Zafrani; Alexis Laurent; Daniel Azoulay; Fouad Lafdil; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2016-08-09       Impact factor: 17.425

2.  Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.

Authors:  Richard Barnett; Valerie S Barta; Kenar D Jhaveri
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

Review 3.  Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.

Authors:  Cameron McDonald-Hyman; Laurence A Turka; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2015-03-25       Impact factor: 17.956

4.  Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.

Authors:  Evan J Lipson; Serena M Bagnasco; Jack Moore; Sekwon Jang; Manisha J Patel; Andrea A Zachary; Drew M Pardoll; Janis M Taube; Charles G Drake
Journal:  N Engl J Med       Date:  2016-03-03       Impact factor: 91.245

5.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321
  5 in total
  15 in total

Review 1.  Liver graft rejection following immune checkpoint inhibitors treatment: a review.

Authors:  Bo Hu; Xiao-Bo Yang; Xin-Ting Sang
Journal:  Med Oncol       Date:  2019-10-11       Impact factor: 3.064

2.  The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.

Authors:  Ioannis A Ziogas; Alexandros P Evangeliou; Lipika Goyal; Georgios Tsoulfas; Dimitrios Giannis; Muhammad H Hayat; Konstantinos S Mylonas; Samer Tohme; David A Geller; Nahel Elias
Journal:  Oncologist       Date:  2021-01-02

3.  Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant.

Authors:  Chimaobi M Anugwom; Thomas M Leventhal; Jose D Debes
Journal:  Hepatoma Res       Date:  2022-02-11

4.  The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.

Authors:  Vivek Kumar; Atul B Shinagare; Helmut G Rennke; Sandeep Ghai; Jochen H Lorch; Patrick A Ott; Osama E Rahma
Journal:  Oncologist       Date:  2020-02-11

Review 5.  Use of checkpoint inhibitors in liver transplant recipients.

Authors:  Stefan Munker; Enrico N De Toni
Journal:  United European Gastroenterol J       Date:  2018-04-30       Impact factor: 4.623

Review 6.  The management of post-transplantation recurrence of hepatocellular carcinoma.

Authors:  Luckshi Rajendran; Tommy Ivanics; Marco Paw Claasen; Hala Muaddi; Gonzalo Sapisochin
Journal:  Clin Mol Hepatol       Date:  2021-10-05

7.  A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen.

Authors:  Jun Yin; Meng Wen; Jun Cheng; Lifen Hu; Li Yang; Xiao Chang; Zhongsong Zhou; Hongbin Li; Yan Liu; Jiabin Li
Journal:  Front Med (Lausanne)       Date:  2022-02-21

8.  Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.

Authors:  Thomas T DeLeon; Marcela A Salomao; Bashar A Aqel; Mohamad B Sonbol; Raquel T Yokoda; Ahmad H Ali; Adyr A Moss; Amit K Mathur; David M Chascsa; Jorge Rakela; Alan H Bryce; Mitesh J Borad
Journal:  J Gastrointest Oncol       Date:  2018-12

9.  Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.

Authors:  Zi-Yun Qiao; Zi-Jie Zhang; Zi-Cheng Lv; Huan Tong; Zhi-Feng Xi; Hao-Xiang Wu; Xiao-Song Chen; Lei Xia; Hao Feng; Jian-Jun Zhang; Qiang Xia
Journal:  Front Immunol       Date:  2021-07-19       Impact factor: 7.561

Review 10.  Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.

Authors:  Yi Luo; Fei Teng; Hong Fu; Guo-Shan Ding
Journal:  World J Gastrointest Oncol       Date:  2022-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.